Potential Savings in the Cost of Caring for Alzheimer's Disease: Treatment with Rivastigmine

Author： Brett Hauber A.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.17, Iss.4, 2000-04, pp. : 351-360

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potential Savings in the Cost of Caring for Alzheimer's Disease: Treatment with Rivastigmine

By Linkins K.W.  

PharmacoEconomics, Vol. 18, Iss. 6, 2000-12 ,pp. : 609-612

Adis International

Access to resources Recommend Favorite

Estimating the Long Term Cost Savings from the Treatment of Alzheimer's Disease: A Modelling Approach

By Neumann P.J.  

PharmacoEconomics, Vol. 17, Iss. 1, 2000-01 ,pp. : 109-109

Adis International

Access to resources Recommend Favorite

Estimating Long Term Cost Savings from Treatment of Alzheimer's Disease: A Modelling Approach

By Fenn P.  

PharmacoEconomics, Vol. 16, Iss. 2, 1999-08 ,pp. : 165-174

Adis International

Access to resources Recommend Favorite

Rivastigmine often underdosed in Alzheimer's disease

By  

Inpharma, Vol. 1, Iss. 1331, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Changes in Metabolite Ratios after Treatment with Rivastigmine in Alzheimer's Disease: A Nonrandomised Controlled Trial with Magnetic Resonance Spectroscopy

By Modrego Pedro J.  

CNS Drugs, Vol. 20, Iss. 10, 2006-01 ,pp. : 867-877

Adis International

Access to resources Recommend Favorite